BNTX vs PCVX
BioNTech SE vs Vaxcyte, Inc. — AI-powered side-by-side comparison
VS
PCVX
Vaxcyte, Inc.
73
Buy
| Metric | BNTX | PCVX |
|---|
| AI Score |
70
|
73
|
| Price |
$91.61
|
$60.23
|
| P/E Ratio |
-11.83×
|
-7.60×
|
| ROE |
-5.7%
|
-28.5%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.9%
|
0.0%
|
| Debt / Equity |
0.02×
|
0.04×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
55.9
|
54.9
|
| Beta |
1.278
|
1.21
|
| Expected Upside |
+6.1%
|
+6.2%
|
AI Committee View
Current Innellis committee reasoning for BNTX versus PCVX.
PCVX leads by 3 points.
PCVX scores 73/100 (Buy) versus BNTX at 70/100 (Buy).
BNTX Committee View
60% agreement
5 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
- VIX regime is low -- calm backdrop supports risk-taking — Macro
Bear Case
- Both daily and weekly trends are bearish — strong multi-timeframe downtrend.
PCVX Committee View
75% agreement
4 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- MACD histogram positive -- bullish momentum — Technical